TG Therapeutics Q1 2026 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 57 minutes ago
0mins
Should l Buy TGTX?
Source: seekingalpha
- Revenue Beat: TG Therapeutics reported approximately $195 million in U.S. BRIUMVI net product revenue for Q1 2026, exceeding guidance of $185 million to $190 million, indicating strong market performance and sustained growth potential.
- Share Buyback Program: The company repurchased $100 million of its stock this quarter, which not only enhances shareholder value but also reflects management's confidence in future growth, likely increasing market recognition of its shares.
- Guidance Upgrade: Following a strong Q1, the company raised its 2026 U.S. revenue guidance to $885 million to $900 million, with global revenue guidance increased to approximately $925 million, signaling optimism about future performance.
- Clinical Trial Progress: Management expects to release top-line data from the ENHANCE study in the coming weeks and plans to launch subcutaneous BRIUMVI by 2028, pending regulatory approval, which could open new market opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to rise
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 36.100
Low
15.00
Averages
43.50
High
60.00
Current: 36.100
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TG Therapeutics Q1 2026 Earnings Call Highlights
- Revenue Beat: TG Therapeutics reported approximately $195 million in U.S. BRIUMVI net product revenue for Q1 2026, exceeding guidance of $185 million to $190 million, indicating strong market performance and sustained growth potential.
- Share Buyback Program: The company repurchased $100 million of its stock this quarter, which not only enhances shareholder value but also reflects management's confidence in future growth, likely increasing market recognition of its shares.
- Guidance Upgrade: Following a strong Q1, the company raised its 2026 U.S. revenue guidance to $885 million to $900 million, with global revenue guidance increased to approximately $925 million, signaling optimism about future performance.
- Clinical Trial Progress: Management expects to release top-line data from the ENHANCE study in the coming weeks and plans to launch subcutaneous BRIUMVI by 2028, pending regulatory approval, which could open new market opportunities for the company.
See More
TG Therapeutics Raises 2026 Revenue Outlook to $925 Million
- Revenue Outlook Raised: TG Therapeutics has raised its full-year 2026 revenue outlook to approximately $925 million from the previous range of $875 to $900 million, reflecting strong confidence in Briumvi sales and indicating significant future growth potential.
- Strong Q1 Performance: The company reported total revenue of $204.9 million for Q1, primarily driven by U.S. Briumvi sales of $194.8 million, exceeding Wall Street's estimate of $201.2 million, which highlights robust market demand for its lead product.
- Clinical Trial Progress: TG expects to report topline Phase 3 results from the Enhance trial of Briumvi around mid-2026, and plans to share early Phase 1 data for azer-cel in progressive multiple sclerosis in the second half of 2026, further enhancing its competitive position in the market.
- Investor Sentiment Shift: Following the release of positive financial guidance, TG Therapeutics' shares surged over 8% in just one day, with retail investor sentiment shifting from 'neutral' to 'extremely bullish', reflecting optimistic expectations for the company's future growth.
See More
TG Therapeutics Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: TG Therapeutics reported a Q1 GAAP EPS of $0.12, missing expectations by $0.15, yet achieved revenues of $204.92 million, reflecting a 69.6% year-over-year increase and surpassing market expectations by $3.71 million, indicating robust market performance.
- Product Revenue Surge: The net product revenue for Q1 2026 reached $201.3 million, significantly up from $119.7 million in Q1 2025, primarily driven by BRIUMVI's sales in the U.S., which totaled $194.8 million, further solidifying its market position.
- Guidance Upgrade: The company raised its full-year 2026 global revenue target to approximately $925 million, exceeding the consensus of $900.34 million, while also increasing the U.S. net product revenue target for BRIUMVI to $885-$900 million, reflecting confidence in future performance.
- Cost Management: The projected operating expenses for 2026, defined as R&D and SG&A, are approximately $350 million, in addition to $100 million associated with BRIUMVI manufacturing costs, indicating effective cost control while pursuing expansion.
See More
TG Therapeutics Set to Announce Q1 Earnings with Strong Revenue Growth
- Earnings Announcement Date: TG Therapeutics is set to release its Q1 earnings on May 6 before market open, with consensus EPS estimated at $0.28 and revenue projected at $201.21 million, reflecting a robust 66.5% year-over-year growth that underscores the company's strong market performance and growth potential.
- Earnings Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions and two downward adjustments, while revenue estimates experienced three upward revisions and two downward changes, indicating market divergence and uncertainty regarding the company's future performance.
- Financing and Buyback Plans: TG Therapeutics recently secured a $750 million credit facility and increased its stock buyback program to $300 million, which not only enhances the company's financial flexibility but may also boost EPS by reducing the number of shares outstanding.
- Future Outlook: The company outlines a revenue guidance of $825 million to $850 million for BRIUMVI by 2026 while accelerating its subcutaneous administration program, indicating a proactive strategic approach in product development and market expansion.
See More
TG Therapeutics to Host Q1 2026 Earnings Call on May 6
- Earnings Call Scheduled: TG Therapeutics will hold a conference call on May 6, 2026, at 8:30 AM ET to discuss Q1 2026 financial results and business outlook, which is expected to impact investor confidence positively.
- CEO to Lead Call: The call will be hosted by CEO and Chairman Michael S. Weiss, aiming to enhance investor interaction and transparency through direct communication.
- Live Webcast and Replay: The presentation will be available via live webcast on the company's website, with an audio recording accessible for 30 days post-call, ensuring that investors unable to attend can still access critical information.
- BRIUMVI® Approval Status: TG Therapeutics' BRIUMVI® (ublituximab-xiiy) has received FDA approval for treating adult patients with relapsing forms of multiple sclerosis, showcasing the company's innovative capabilities and market potential in the biotechnology sector.
See More
TG Therapeutics Presents New Data on BRIUMVI at AAN 2026
- Clinical Data Presentation: TG Therapeutics showcased new data on BRIUMVI (ublituximab-xiiy) at the 2026 American Academy of Neurology annual meeting, emphasizing its advantages in safety and tolerability, which may further solidify its market position.
- Supporting Research Findings: Results from the ENABLE and ENHANCE studies demonstrate BRIUMVI's effectiveness and safety in real-world settings, providing insights into optimized IV dosing regimens that could encourage increased physician adoption.
- Expert-Led Studies: Key poster presentations were led by Dr. Carrie Hersh from Cleveland Clinic and Dr. Barry Singer from Missouri Baptist Medical Center, highlighting the significance of BRIUMVI in clinical applications and its potential impact on treatment protocols.
- Market Potential: As a treatment option for relapsing forms of multiple sclerosis, BRIUMVI is expected to attract more patients, particularly in the U.S., where the prevalence of the disease approaches 1 million, indicating substantial market demand.
See More
TG Therapeutics Q1 2026 Earnings Call Highlights
- Revenue Beat: TG Therapeutics reported approximately $195 million in U.S. BRIUMVI net product revenue for Q1 2026, exceeding guidance of $185 million to $190 million, indicating strong market performance and sustained growth potential.
- Share Buyback Program: The company repurchased $100 million of its stock this quarter, which not only enhances shareholder value but also reflects management's confidence in future growth, likely increasing market recognition of its shares.
- Guidance Upgrade: Following a strong Q1, the company raised its 2026 U.S. revenue guidance to $885 million to $900 million, with global revenue guidance increased to approximately $925 million, signaling optimism about future performance.
- Clinical Trial Progress: Management expects to release top-line data from the ENHANCE study in the coming weeks and plans to launch subcutaneous BRIUMVI by 2028, pending regulatory approval, which could open new market opportunities for the company.
See More
TG Therapeutics Raises 2026 Revenue Outlook to $925 Million
- Revenue Outlook Raised: TG Therapeutics has raised its full-year 2026 revenue outlook to approximately $925 million from the previous range of $875 to $900 million, reflecting strong confidence in Briumvi sales and indicating significant future growth potential.
- Strong Q1 Performance: The company reported total revenue of $204.9 million for Q1, primarily driven by U.S. Briumvi sales of $194.8 million, exceeding Wall Street's estimate of $201.2 million, which highlights robust market demand for its lead product.
- Clinical Trial Progress: TG expects to report topline Phase 3 results from the Enhance trial of Briumvi around mid-2026, and plans to share early Phase 1 data for azer-cel in progressive multiple sclerosis in the second half of 2026, further enhancing its competitive position in the market.
- Investor Sentiment Shift: Following the release of positive financial guidance, TG Therapeutics' shares surged over 8% in just one day, with retail investor sentiment shifting from 'neutral' to 'extremely bullish', reflecting optimistic expectations for the company's future growth.
See More
TG Therapeutics Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: TG Therapeutics reported a Q1 GAAP EPS of $0.12, missing expectations by $0.15, yet achieved revenues of $204.92 million, reflecting a 69.6% year-over-year increase and surpassing market expectations by $3.71 million, indicating robust market performance.
- Product Revenue Surge: The net product revenue for Q1 2026 reached $201.3 million, significantly up from $119.7 million in Q1 2025, primarily driven by BRIUMVI's sales in the U.S., which totaled $194.8 million, further solidifying its market position.
- Guidance Upgrade: The company raised its full-year 2026 global revenue target to approximately $925 million, exceeding the consensus of $900.34 million, while also increasing the U.S. net product revenue target for BRIUMVI to $885-$900 million, reflecting confidence in future performance.
- Cost Management: The projected operating expenses for 2026, defined as R&D and SG&A, are approximately $350 million, in addition to $100 million associated with BRIUMVI manufacturing costs, indicating effective cost control while pursuing expansion.
See More
TG Therapeutics Set to Announce Q1 Earnings with Strong Revenue Growth
- Earnings Announcement Date: TG Therapeutics is set to release its Q1 earnings on May 6 before market open, with consensus EPS estimated at $0.28 and revenue projected at $201.21 million, reflecting a robust 66.5% year-over-year growth that underscores the company's strong market performance and growth potential.
- Earnings Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions and two downward adjustments, while revenue estimates experienced three upward revisions and two downward changes, indicating market divergence and uncertainty regarding the company's future performance.
- Financing and Buyback Plans: TG Therapeutics recently secured a $750 million credit facility and increased its stock buyback program to $300 million, which not only enhances the company's financial flexibility but may also boost EPS by reducing the number of shares outstanding.
- Future Outlook: The company outlines a revenue guidance of $825 million to $850 million for BRIUMVI by 2026 while accelerating its subcutaneous administration program, indicating a proactive strategic approach in product development and market expansion.
See More
TG Therapeutics to Host Q1 2026 Earnings Call on May 6
- Earnings Call Scheduled: TG Therapeutics will hold a conference call on May 6, 2026, at 8:30 AM ET to discuss Q1 2026 financial results and business outlook, which is expected to impact investor confidence positively.
- CEO to Lead Call: The call will be hosted by CEO and Chairman Michael S. Weiss, aiming to enhance investor interaction and transparency through direct communication.
- Live Webcast and Replay: The presentation will be available via live webcast on the company's website, with an audio recording accessible for 30 days post-call, ensuring that investors unable to attend can still access critical information.
- BRIUMVI® Approval Status: TG Therapeutics' BRIUMVI® (ublituximab-xiiy) has received FDA approval for treating adult patients with relapsing forms of multiple sclerosis, showcasing the company's innovative capabilities and market potential in the biotechnology sector.
See More
TG Therapeutics Presents New Data on BRIUMVI at AAN 2026
- Clinical Data Presentation: TG Therapeutics showcased new data on BRIUMVI (ublituximab-xiiy) at the 2026 American Academy of Neurology annual meeting, emphasizing its advantages in safety and tolerability, which may further solidify its market position.
- Supporting Research Findings: Results from the ENABLE and ENHANCE studies demonstrate BRIUMVI's effectiveness and safety in real-world settings, providing insights into optimized IV dosing regimens that could encourage increased physician adoption.
- Expert-Led Studies: Key poster presentations were led by Dr. Carrie Hersh from Cleveland Clinic and Dr. Barry Singer from Missouri Baptist Medical Center, highlighting the significance of BRIUMVI in clinical applications and its potential impact on treatment protocols.
- Market Potential: As a treatment option for relapsing forms of multiple sclerosis, BRIUMVI is expected to attract more patients, particularly in the U.S., where the prevalence of the disease approaches 1 million, indicating substantial market demand.
See More
